We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
The most recent trading session ended with DaVita HealthCare (DVA - Free Report) standing at $141.12, reflecting a -1.06% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and the Nasdaq, a tech-heavy index, lost 1.96%.
Shares of the kidney dialysis provider witnessed a loss of 17.08% over the previous month, trailing the performance of the Medical sector with its loss of 1.88% and the S&P 500's loss of 7.38%.
Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. It is anticipated that the company will report an EPS of $1.75, marking a 26.47% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $3.23 billion, indicating a 5.27% increase compared to the same quarter of the previous year.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $10.76 per share and revenue of $13.47 billion. These results would represent year-over-year changes of +11.16% and +5.08%, respectively.
It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.24% lower. Currently, DaVita HealthCare is carrying a Zacks Rank of #3 (Hold).
Investors should also note DaVita HealthCare's current valuation metrics, including its Forward P/E ratio of 13.25. This represents a discount compared to its industry's average Forward P/E of 19.54.
Investors should also note that DVA has a PEG ratio of 1.05 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Outpatient and Home Healthcare industry held an average PEG ratio of 1.81.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 51, finds itself in the top 21% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita HealthCare (DVA) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with DaVita HealthCare (DVA - Free Report) standing at $141.12, reflecting a -1.06% shift from the previouse trading day's closing. This move lagged the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and the Nasdaq, a tech-heavy index, lost 1.96%.
Shares of the kidney dialysis provider witnessed a loss of 17.08% over the previous month, trailing the performance of the Medical sector with its loss of 1.88% and the S&P 500's loss of 7.38%.
Market participants will be closely following the financial results of DaVita HealthCare in its upcoming release. It is anticipated that the company will report an EPS of $1.75, marking a 26.47% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $3.23 billion, indicating a 5.27% increase compared to the same quarter of the previous year.
DVA's full-year Zacks Consensus Estimates are calling for earnings of $10.76 per share and revenue of $13.47 billion. These results would represent year-over-year changes of +11.16% and +5.08%, respectively.
It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 4.24% lower. Currently, DaVita HealthCare is carrying a Zacks Rank of #3 (Hold).
Investors should also note DaVita HealthCare's current valuation metrics, including its Forward P/E ratio of 13.25. This represents a discount compared to its industry's average Forward P/E of 19.54.
Investors should also note that DVA has a PEG ratio of 1.05 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Outpatient and Home Healthcare industry held an average PEG ratio of 1.81.
The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 51, finds itself in the top 21% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.